Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Leo Miller

Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial

[content-module:CompanyOverview|NYSE:LLY]

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025, with a total return of 12% as of the Feb. 11 close. Contributing meaningfully to the stock's rise so far this year was the firm’s Q4 2024 earnings report on Feb. 6. Sales of the company’s GLP-1 drugs are still red-hot.

But does this mean a rally in Eli Lilly is likely to continue? Below, I’ll discuss essential points from the earnings report and management commentary. I’ll then provide an outlook on the company's shares.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.